DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactResults

Concord Biotech Limited — Outcome of Board Meeting

NSE 2 hrs ago·31 Jul 2026, 12:48 pm

Concord Biotech

Concord Biotech Limited has informed the stock exchange about its financial results for the period ending June 30, 2026. This filing marks the formal disclosure of the company's performance during this specific quarter, which is a routine update for publicly listed entities.

This announcement is significant for investors as it provides the latest data on the company's operational health and financial standing. By reviewing these figures, stakeholders can assess the firm's current trajectory and make more informed decisions regarding their portfolio.

Investors should focus on the key metrics within the report, such as revenue growth and profit margins, to gauge the company's performance. Keeping an eye on future guidance and market trends will be essential for understanding the stock's next steps.